AAA March 2013 – Page 5

CrunchFund invests in Handshakez

US-based collaboration and analytics Platform Handshakez, has raised $3.6m in A round financing led by Austin Ventures and with involvement from AOL’s CrunchFund.

A Brit abroad

Personally, it was wonderful to see so many subscribers to Global Corporate Venturing in the room as my visa was predicated on the publication having more than half its revenues and customers from the US. My thanks also to so many of the others attending who signed up to subscribe afterwards.

Man in the news: Mark Heesen, the frequent flyer

Perhaps the most telling fact about Mark Heesen, who is retiring, having been head of the US trade body National Venture Capital Association [NVCA] for about 14 years, is that he has clocked up nearly two million frequent flyer miles. The praise Heesen has received from people in the venture and corporate venturing industry appears… Continue reading Man in the news: Mark Heesen, the frequent flyer

See Me noticed for seed

See Me, a US-based social network for creative media people formerly known as Artists Wanted, has raised $900,000 in its seed round from a consortium including local publisher O’Reilly AlphaTech’s corporate venturing unit. Alongside O’Reilly AlphaTech Ventures (OATV) in the seed round were venture capital firm Founder Collective and angel investor Joshua Stylman, according to… Continue reading See Me noticed for seed

Kilopass remembers its $8m

Kilopass Technology, a US-based provider of computer memory, has raised $8m from a “major consumer electronics licensee”. Charlie Cheng, chief executive of Kilopass, said: “We have worked closely with our 150 licensees across consumer, mobility, analog mixed signal, automotive, and industrial markets to address their embedded NVM [semiconductor logic non-volatile memory] needs.” Kilopass is also… Continue reading Kilopass remembers its $8m

Presage Biosciences heralds $8m

Presage Biosciences, a US-based developer of drugs for cancers in animals, has sold a minority stake worth $8m to peer Celgene. Celgene is also investing an initial $5m to help pay for Presage’s clinical trials with more available if performance targets are hit. Thomas Daniel, president of research and early development at Celgene, said: “Drug… Continue reading Presage Biosciences heralds $8m